CDKN2A and hepatoblastoma: Studies using hepatoblastoma cells or human embryonic kidney (HEK) cells and HBx-expressing plasmid demonstrated p16INK4a repression (Kim et al., 2010), p38MAPK activation (Kim et al., 2007), or aberrant NFκB signaling (Shukla et al., 2011).